- Phase I
- Phase II/III
- Therapeutic expertise
- Rescue services
- Technology solutions
- Comprehensive capabilities
- News &
Therapeutic Focus: Respiratory
Respiratory Trial Experience
Rho has conducted over 75 studies with more than 600 sites and including more than 16,000 subjects. Rho has experience with a broad range of respiratory indications, including the following areas:
- Allergic rhinitis
- Lung cancer
- Pulmonary hypertension
- Cystic fibrosis
- Lung transplantation
- Sleep apnea
Site and Investigator Relationships
Through our extensive experience, we have developed strong relationships with high performing sites. High enrolling sites with trained investigators and staff allow us to consistently meet or exceed our sponsors’ study start-up timelines.
Publication and Research Accomplishments
Rho scientists have published more than 30 articles in peer-reviewed journals related to respiratory diseases and research. These journals include:
- New England Journal of Medicine
- The Lancet
- Journal of Allergy and Clinical Immunology
- Clinical and Molecular Allergy
- BMC Pulmonary Medicine
- American Journal of Respiratory and Critical Care Medicine
- Pediatric Pulmonology
- Journal of Asthma
- Pulmonary Pharmacology and Therapeutics
- Clinical and Experimental Allergy
- Journal of Clinical Microbiology
- PLoS ONE
- BMC Immunology
- Archives of Pediatrics and Adolescent Medicine
- American Journal of Public Health
- Environmental Health Perspectives
- Ambulatory Pediatrics
Click here for a complete listing of our publications, presentations, and white papers.
Meet Our Experts
This Medical Monitor is a board-certified internist who is also certified in Pulmonary and Sleep Medicine. As an Adjunct Professor of Medicine, he maintains close ties with the University of North Carolina at Chapel Hill School of Medicine after serving as a professor in the Division of Pulmonary Medicine for 27 years. He has 35 years of experience in clinical medicine and research and has served as a Medical Monitor on Phase I to Phase III studies. He also has handled the medical aspects for Phase I-IV clinical studies including, protocol and data collection document development, training of site personnel, resolving site questions regarding inclusion/exclusion criteria, and final review of results and clinical study reports.
This Research Scientist received her doctorate in Pharmacology and Physiology from the University of Rochester, where she studied hematopoietic cells and has since spent over 13 years conducting asthma-related research. While working with the American Academy of Allergy, Asthma and Immunology (AAAAI), she helped coordinate and write the Allergy Report based on evidence, guidelines, and consensus, and involving experts from numerous national organizations. She also served as part of a national program office for the AAAAI Robert Wood Johnson Foundation-funded project, Pediatric Asthma: Emergency Department Demonstration Program. At Rho, she has been responsible for coordinating research activities for large, multi-center asthma studies, including studies focusing on microbial exposure as it relates to immune development and translating evidence-based environmental interventions into the community setting.
This Program Manager received her doctorate in Cell and Molecular Physiology from the University of North Carolina at Chapel Hill. Her research was completed within a laboratory at the Cystic Fibrosis Center and focused on airway physiology. She has spent the past six years in the pharmaceutical industry, specializing in clinical aspects of pharmaceutical development. She has managed multiple cross-functional clinical study teams and has clinical operations and monitoring experience. She has worked on studies for respiratory indications including cystic fibrosis and allergic rhinitis.
Scientific Program Advisor
This Scientific Program Advisor brings more than 25 years of experience in the pharmaceutical industry, specializing in clinical pharmaceutical development and respiratory research. During this time, she has led multiple integrated drug-development programs spanning the development spectrum, including planning, managing, and overseeing all aspects of drug development, leading to multiple NDAs. During her 10-year tenure at a mid-size biopharmaceutical company, she led the global efforts to investigate a novel inhaled therapy for the treatment of cystic fibrosis. In addition, she has been instrumental in leading clinical efforts for several marketed respiratory compounds.
Click here to download